3 Australian Growth Stocks With Revenue Growth Up To 46%

As investors debate the risks around AI driven companies, Anthropic’s huge planned IPO is a reminder that markets still reward growth stories backed by confident management teams. That same idea sits behind fast growing Australian businesses where insiders hold meaningful stakes. When founders have serious skin in the game, their incentives are closer to yours. This article walks through three of the most interesting stocks from that group.

The three stocks highlighted here offer a compelling starting point if you want exposure to fast growing businesses where leadership is clearly aligned with shareholders. However, if you want the names that matter most, these 26 high growth high conviction stocks are the strongest companies we've found.

Regis Healthcare (ASX:REG)

Regis Healthcare runs residential aged care homes and at home support services across Australia, closely tied to the ageing population theme that underpins this screener, and generates about A$1.35b in revenue from care services with a market value near A$1.44b.

For investors focused on growth supported by aligned insiders, Regis Healthcare links revenue directly to Australia’s ageing demographics through its network of care homes, home care packages and retirement villages, which is the type of exposure this theme is built around.

While the new 2% RAD retention framework and higher advertised room prices support a growing capital-like earnings stream, any change in government policy settings around RADs or retention rates would directly affect this contribution to EBITDA and long term earnings.

What matters now is how one unseen pressure shapes future pricing power and the headroom for margins over the next few years.

That pricing power question is exactly what the full narrative for Regis Healthcare unpacks, revealing how regulation, capital flows and operator choices could reshape Regis Healthcare’s earnings mix.

PDI Gold (ASX:PDI)

PDI Gold is a West African gold producer and refiner focused on the Kiniéro Gold Mine in Guinea, which anchors its growth profile within this screener’s theme of high insider alignment and confident management outlooks.

PDI Gold generates about $156 million from Kiniéro and $47 million from Nampala, giving investors exposure to two producing hubs, and the stock is valued at roughly A$3.76 billion.

For investors drawn to fast growing operations backed by optimistic management, PDI Gold illustrates that narrative through its Kiniéro production ramp and sizeable resource base that supports expectations for rising output and future cash generation.

Although Kiniero is ramping strongly with low reported all in sustaining costs and high throughput, the reliance on oxide ore for the next few years means a later shift to harder material could lift unit costs and pressure margins once the current "oxide holiday" ends.

What happens when the current mix of ore changes will indicate whether today’s reported economics translate into durable margins as the mine matures.

That inflection point is exactly where the full narrative for PDI Gold maps how PDI Gold’s oxide window, capital plans and insider alignment could turn today’s economics into accelerating long term cash power.

Telix Pharmaceuticals (ASX:TLX)

Telix Pharmaceuticals gives this screener a pure play on fast-growing radiopharmaceuticals, with late-stage cancer imaging and treatment assets that already touch real patients and underpin genuine commercial traction rather than distant blue-sky promises.

Telix Pharmaceuticals develops and commercialises radiopharmaceutical diagnostics and therapies, with the Fast Growing Stocks With High Insider Ownership theme most closely tied to its late-stage prostate cancer portfolio and approved imaging agents. The group generated about $705 million from Precision Medicine and $277 million from Manufacturing Solutions, and is valued at roughly A$4.37b.

They are vertically integrating manufacturing and distribution through a handful of acquisitions (RLS, ARTMS, Iso Therapeutics). Less reliance on third parties may mean better margins and more supply reliability over time.

What investors are really weighing now is how one still unresolved pressure on future pricing power and profitability unfolds as that footprint scales.

That unresolved pressure is exactly what the full narrative for Telix Pharmaceuticals unpacks, showing how Telix Pharmaceuticals could turn vertical integration into accelerating pricing power while managing the real risks around execution and regulation.

Seeking Alternatives Before Markets Catch On

Fresh ideas move first. Stocks with quiet momentum can flip into full breakout mode before slow money even looks. Scan what is still under the radar for now and act now.

• Spot income workhorses before yields get compressed by late money by using the curated 4 dividend fortresses built to surface payouts that still look sustainable.
• Track where AI profits are already flowing, not just promised, by running through the hand picked 39 profitable AI stocks that aren't just burning cash that screens out cash burners.
• Position ahead of potential supply pinch points by checking the focused 16 top copper producer stocks that filters for established producers in this critical metal.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com